![]() ![]() Co-payments, or co-pays, are fixed dollar amounts that patients pay for many prescription drugs and health services such as office visits, and often do not count toward a deductible. Many biosimilar companies will have less time to gauge the market to determine a launch price.Īdditionally, AbbVie has been gradually raising the US price of Humira over the past few years, increasing its wholesale acquisition cost by 7.3% and its net price by 9.6% between 20.Ĭo-payments and coinsurance can be a tricky field to navigate because they are determined by health insurers, also known as payers. In July 2023, between 5 and 9 biosimilars are expected to launch. However, for the first 6 months of biosimilar competition, Humira will only face 1 competitor, making it difficult to tell exactly how much of a price reduction biosimilars will cause in the long run. 1Įven more impressive, the threat of biosimilar competition has been enough to get AbbVie to lower its price for Humira up to 80% in some international markets. One analysis published by The Journal of Pharmaceutical Sciences showed that after the first quarter of 2020, when compared with the Humira’s list price 1 year before biosimilar market entry, adalimumab biosimilars averaged net price reductions from the reference product ranging from 15% to 29% in France to over 50% in Denmark, Germany, Hungary, Italy, Poland, and Sweden. In Europe, where 10 adalimumab biosimilars compete against Humira, there’s more hope for biosimilar discounts. However, biosimilars in the US immunology space, such as those referencing Remicade (infliximab) tend to launch at a 19% to 25% discount from the reference product. Overall, list price discounts for biosimilars average about 30% to 40% lower than the reference products. ![]() Additionally, AbbVie, the maker of Humira, will also have to determine whether to lower its price for Humira to compete against the biosimilars. Price discounts of biosimilars and reference productsĪs biosimilars enter the market, companies developing these competitors will have to set launch prices, which will likely be considerably lower than Humira.However, whether those savings will impact patients directly depends on a few things: Projections show that adalimumab biosimilars could generate $19.3 billion in savings by 2025, a 50% share of the total amount of saving expected from biosimilars between 20. Will Patients See Savings, and How Much Is Expected? This second installment in a 4-part series examines how the introduction of adalimumab biosimilars will impact patients and employers and the steps each group can take now to prepare. This month, The Center for Biosimilars ® is looking at all aspects of what the launch of adalimumab biosimilars in the US market will mean for stakeholders, from lessons learned in other markets to the need to hear from providers who must decide whether to prescribe new products. Will these lower prices be offered to patients? Will patients be forced to switch therapies? Is switching from a reference product to a biosimilar safe? How will interchangeability influence prescribing habits? What role can employers play in ensuring patient satisfaction and substantial savings? However, there are many aspects of this competition that are still flying under the radar. As the year unfolds, between 7 and 12 adalimumab biosimilars will launch on the US market, and all are slated to be priced at a significant discount to the originator. Starting in 2023, patients receiving therapy with Humira (adalimumab) will have several lower-cost options available. ![]() Readers can also check out part 1, part 3, part 4, podcast 1, and podcast 2 now. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |